Replies to post #360 on Vascular Biogenics Ltd (VBLT)

[gr8db8]

That day will come. VBLT wants VB-111 to be first line treatment, but they need to conquer the rGBM beast first and show that VB-111 is well tolerated (which it is). If VB-111 is tolerated in the recurrent (less healthy) population, I would think it would be well tolerated in the healthier population.